Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Kura Oncology (KURA) Stock Price
News stories about Kura Oncology (NASDAQ:KURA) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kura Oncology earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.7318513521885 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Kura Oncology (NASDAQ KURA) traded up $0.55 on Wednesday, reaching $16.60. The company had a trading volume of 278,700 shares, compared to its average volume of 180,910. The stock has a market capitalization of $501.58 and a price-to-earnings ratio of -10.71. Kura Oncology has a 12 month low of $5.78 and a 12 month high of $17.50. The company has a current ratio of 13.48, a quick ratio of 13.48 and a debt-to-equity ratio of 0.07.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). analysts predict that Kura Oncology will post -1.52 earnings per share for the current year.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.